With the introduction of PARP inhibitors for treating breast and ovarian cancers, the presence or absence of the germline BRCA1/2 pathogenic variant is being determined for appropriate drug selection [21,22,23,24,25,26,27,28,29,30,31,32,33,34]. The gene discussed is PARP1; the disease is ovarian carcinoma.